CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery
Portfolio Pulse from Benzinga Newsdesk
CytoSorbents has submitted a De Novo marketing application to the FDA for its DrugSorb-ATR medical device. This device aims to reduce perioperative bleeding in patients on Ticagrelor undergoing coronary artery bypass graft surgery.
October 01, 2024 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytoSorbents has submitted a De Novo marketing application to the FDA for its DrugSorb-ATR device, which could reduce bleeding in patients on Ticagrelor during coronary surgery.
The submission of a De Novo marketing application to the FDA is a significant step for CytoSorbents, as approval could lead to increased adoption of their DrugSorb-ATR device. This could positively impact CTSO's stock price in the short term due to potential future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100